The Latest Breaking News from Viatris

Viatris is set to report its fourth-quarter earnings soon, with analysts forecasting a slight decline in profits.

As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. (NASDAQ:VTRS) on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Viatris is scheduled to release its fourth-quarter earnings next month, and analysts anticipate a profit dip.